



Press release

Stockholm, Aug 7, 2012

Interim Report – January to June 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody[®] molecules and Albumod[™], today issued its Interim Report covering the First Half of 2012.

Financial Highlights

- Revenue for the first six months of 2012 was SEK 28.5 (14.2) million
- EBITDA for the period amounted to SEK 9.0 (-2.5) million
- Net result for the period amounted to SEK 4.4 (-8.0) million
- Cash flow from current operations was SEK 8.0 (-1.0) million

Key Corporate Highlights

- After the period on July 10th Affibody and Swedish Orphan Biovitrum (“SOBi”) announced a broad collaboration focused on IL-1 biology.
- In connection with the ASCO meeting in early June, GE Healthcare and Affibody announced a collaboration focused on the development of a HER2-targeted PET imaging agent.
- Earlier in the year, Affibody and Creative Antibiotics announced an agreement to develop pharmaceutical candidates targeting gram negative bacteria.

David Beijker CEO, said: *“We have recently had the pleasure to announce both a clinical collaboration with the market leader in medical imaging, GE Healthcare, and a broad IL-1 collaboration with a company that has a leading position in that niche, SOBi. These collaborations provide both revenue in the short term and significant success based payments in the years ahead, but more importantly they provide a foundation for continued development of our technology and a validation of our organization and our platforms.”*

Enquiries

David Beijker, CEO
Johan Stuart CFO

+46 706 454 948
+46 706 644 096

About Affibody

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody[®] molecules and Albumod[™].

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod[™], for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: www.affibody.com



Gunnar Asplunds allé 24, SE-171 63 Solna, Sweden.
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, www.affibody.com